French Hospital Network Unicancer Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
ClearRT is a novel, helical CT imaging solution designed to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively. Because high-quality images are crucial to each step of the radiotherapy treatment workflow, the ability to "See More, Know More, and Do More," when treating tumors with radiation will enable medical care teams to improve patient care. ClearRT also integrates with other
"Unicancer is one of our largest customers with over 30
Unicancer is the only French hospital network 100 percent dedicated to the treatment of cancer. The more than 30 Accuray TomoTherapy and CyberKnife platform systems in use by Unicancer medical care teams provide them with the flexibility to deliver radiation using a variety of methods – from image-guided intensity-modulated radiation therapy (IG-IMRT) to stereotactic body radiation therapy (SBRT) and conventionally fractionated to hypofractionated treatments – depending on each patient's unique needs.
"Unicancer is a busy network of cancer centers focused on providing the more than 530,000 patients we treat each year with the best possible care. Our teams are committed to identifying and using advanced radiotherapy techniques that make it possible to offer patients more targeted and less invasive treatments," said
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Unicancer is the only French hospital network dedicated 100% to the fight against cancer and the only national hospital federation dedicated to oncology. It brings together the 18 French Cancer Centers (CLCC), private non-profit health establishments, spread over 20 hospital sites in
The CLCCs take care of nearly 530,000 patients per year (short-stay, HAD and outpatient procedures).
Unicancer is also the leading academic promoter of clinical trials in oncology, on a European scale, with 106 active clinical trials promoted, nearly 7,600 patients included, 63,000 patients registered in the ESME database. Recognized as a research leader in
The 18 CLCCs and Unicancer's R&D department are ISO 9001 certified.
To find out more: www.unicancer.fr
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
+1 (408) 789-4426
+1 (703) 297-7194
View original content to download multimedia:https://www.prnewswire.com/news-releases/french-hospital-network-unicancer-acquires-multiple-accuray-radixact-systems-with-the-clearrt-helical-fan-beam-kvct-imaging-and-synchrony-technologies-301387518.html